Commentary: From boardroom to courtroom: maximising your return - by Hitesh Patel and Simon tottman of KPMG
This article was originally published in Scrip
Executive Summary
Pharmaceutical companies are revising their operating models in order to reduce costs and take advantage of fresh opportunities. For example, outsourcing to lower cost jurisdictions and joint-venture developments to manage the risk of large R&D investments.